The present work provides an overview about the potentiality of differently substituted 3-amidocoumarins in the neurodegenerative diseases. The inhibitory activity of MAOs, as well as the reversibility of the inhibition, the neuroprotective effects on neuronal cells against H 2 O 2 , the antioxidant effect measured by DPPH free radical scavenging of 3-amidocoumarins, and the cross through blood-brain barrier for the most potent derivatives, have been evaluated. Many of these derivatives proved to be capable of selectively inhibiting the MAO-B isoenzyme. Substitution at position 4 with a hydroxyl group leads to a loss of activity of the 3-benzamidocoumarins against this 2 enzyme, but favours their neuroprotective activity against H 2 O 2 . Regarding the 3-heteroarylamide derivatives, it was the nature of the heterocycle that determined its neuroprotective effects. Although none of the studied derivatives violated the theoretical Lipinski's rules, the parallel artificial membrane permeation assay showed that not every compound could efficiently cross the blood-brain barrier. However, this new scaffold presented, in general, desirable properties for the development of potential drug candidates against neurodegenerative diseases.
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Abstract:
The present work provides an overview about the potentiality of differently Alzheimer's disease (AD). [1] Their chronic course produces a gradual but steady deterioration whose last step is death. [2] Because of this, as the disease progresses, it
is eroding the quality of life of patients. [3] Therefore, the development of effective neuroprotective therapies that slow down or stop disease's progression in the earliest stages is one of the main goals of the researchers in this area. [4] At the cellular level, PD is related to excess production of reactive oxygen species (ROS), to alterations in catecholamine metabolism, to modifications in mitochondrial electron transporter chain (METC) function or to enhancement of iron deposition in the SNpc. [5] The failure of normal cellular processes that occur in relation to the aging are also believed to contribute to the increased vulnerability of dopaminergic (DA) neurons. [6] Although the precise mechanism corresponding to ROS generation related to PD is still unknown, the major sources of oxidative stress generated by the DA neurons are DA metabolism, mitochondrial dysfunction, and neuroinflammation. [7] Metabolism of DA by monoamine oxidase (MAO) yields hydrogen peroxide (H 2 O 2 ), an oxygen radical that leads to cytotoxicity through peroxidation of lipid membranes.
Selegiline and rasagiline, two selective MAO-B inhibitors are currently used to retard the symptoms in PD because they increase the dopamine levels and may exert neuroprotective effects. Inhibition of MAO-B reduces oxygen radical generation although new neuroprotective functions independently of inhibiting MAO activity have been reported for these drugs. [8] The occurrence of oxidative stress in PD patients is supported by postmortem studies and by preclinical studies showing the ability of oxidizing toxins to induce cell death in the substantia nigra. [9] Accordingly, antioxidants that scavenge free radicals and reactive species such as tocopherol and ascorbate may have beneficial therapeutic effects in PD by preventing the onset of apoptotic cell death and neuronal degeneration of the dopaminergic nigrostriatal pathway. [10] Nonetheless, all approved PD pharmacotherapies have limited efficacy, do not prevent the progression of the disease, and are associated with adverse motor and non-motor side effects. [11] Accordingly, there is an urgent need to develop novel therapies that are superior to the current therapies.
Since the beginning of medicine, the nature has played a key role as source of inspiration in the development of drugs with important biological activities. Coumarins (2H-1-benzopyran-2-one), common metabolites in plants (also detected in microorganisms and animal sources), [12] have shown great interest, in particular due to several pharmacological activities that they may display. [13] The pharmacological and biochemical properties, and therapeutic applications of simple coumarins depend on the various substitutions of the scaffold. [13] Of thousands of different coumarins currently existent, some natural or obtained by chemical synthesis have been evaluated in many different pharmacological targets of great interest in the field of medicinal chemistry. [14] Therefore, there are coumarins as antioxidants and antiinflammatories, [15] neuroprotective agents, [16, 17] antidepressants, [18] anticonvulsants, [19] antibacterials, [20] antivirals, [21] anticancer agents, [22, 23] anticoagulants, [24] antihypertensives [25] and enzyme inhibitors, [26] [27] [28] [29] [30] [31] [32] [33] among others. More recently it has been found that simple coumarins, usually substituted at positions 3, 4, 6, 7 or 8 have properties such as MAO inhibitors, which makes them an interesting option in the search for new drugs for the treatment of ND. [27] [28] [29] [30] [31] [32] [33] In recent years, simple coumarins substituted at positions 3 or 4 have been described by exhibiting activity as inhibitors of cholinesterases (ChE), both acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE). The planarity and aromaticity of these derivatives proved to be essential for the activity. The substitution at these positions of the coumarin ring also allowed interesting derivatives resulting β-secretase 1 (BACE-1) inhibitors. [26, 29] All these properties encouraged our group to study differently substituted coumarins as lead compounds with potential interest for ND's therapeutics. Therefore, our research group has been working, in recent years, in the study of 3-substituted coumarins with activity on different targets involved in ND. The introduction of an amide group as a linker between the coumarin skeleton and a phenyl at position 3 has allowed the obtaining of coumarins with dual activity as MAO and ChE inhibitors. [29] The introduction of hydroxyl groups in the molecule enhanced their antioxidant properties. [34] Taking into account the background of our research group (Figure 1 ), [28] [29] [30] [31] [32] [33] 
Results and Discussion
Chemistry
The described derivatives were efficiently synthesized according to the protocol outlined in Scheme 1. hydroxycoumarin, in ethanol, with Pd/C as catalyst, in H 2 atmosphere, for 5 hours, with a yield of 90%. [35, 36] An acylation of the 3-aminocoumarins with the conveniently substituted acid chloride, using pyridine in dichloromethane, from 0 °C to room temperature, afforded the differently 3-substituted coumarins (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) in yields between 80 and 90%. [32, [37] [38] [39] [40] [41] [42] The reaction conditions and chemical characterization of the new compounds are detailed in the experimental section. 
Pharmacology
MAO in vitro inhibition
The biological evaluation of the test drugs on hMAO activity was investigated by measuring their effects on the production of H 2 O 2 from p-tyramine (a common substrate for hMAO-A and hMAO-B), using the Amplex ® Red MAO assay kit and microsomal MAO isoforms prepared from insect cells (BTI-TN-5B1-4) infected with recombinant baculovirus containing cDNA inserts for hMAO-A or hMAO-B. [43] The production of H 2 O 2 catalysed by the two MAO isoforms can be detected using 10- 50 value is the mean ± S.E.M. from five experiments (n = 5).
[b] Selectivity index: MAO-B selectivity ratios [IC 50 (MAO-A)]/[IC 50 (MAO-B)] for inhibitory effects of both new compounds and reference inhibitors.
[c] p <0.01 regarding the corresponding IC 50 obtained against MAO-B as determined by ANOVA/Dunnett's. [d] Values obtained under the assumption that the corresponding IC 50 against either MAO-A or MAO-B is major than 100 µM. * Inactive at 100 µM (highest concentration tested). ** 100 µM inhibits enzymatic activity by approximately 50-55%. At higher concentrations the compounds precipitate.
As shown in Table 1 , many of the studied compounds displayed selective inhibitory activity against hMAO-B in the micromolar range, being the compound 1 the most active derivative of the series (IC 50 = 0.76 µM). Regarding the 3-benzamidocoumarins and comparing with previously published results, [29] it was observed that, in general, the introduction of a hydroxyl group at position 4 of the coumarin scaffold resulted in a loss of activity against hMAO-B, lacking this activity the derivatives 2-5, 7 and 9. In fact, from this series, only compound 6 presented hMAO-B inhibitory activity (IC 50 
Reversibility assay
Reversibility experiments were performed to evaluate the type of inhibition of derivatives 1, 12, 14 and 17 ( Table 2 ). These compounds were selected based on their structure and activity against hMAO-B. An effective dilution method was used, and selegiline (irreversible inhibitor) and isatin (reversible inhibitor) were taken are standards. [44, 45] hMAO-B inhibition was proved to be reversible in the presence of compounds 1, 12, 14 and 17, being their degree of reversibility lower than that described for isatin (reversible reference compound). Results are expressed as mean ± S.E.M from at least 5 experiments. * P <0.05, ** P <0.001 versus the corresponding viability obtained in the control group treated with DMSO.
Neuronal survival
Then, the neuroprotective effect of compounds 1-17 was assessed in cultured rat cortical neurons exposed to H 2 O 2 . Neurons incubated or not with compounds 1-17 (100 μM), were exposed to H 2 O 2 (30 μM) at the same time point and incubated for 24 hours.
The toxin treatment group in the cell viability assays showed a significant difference in production of toxicity compared to those treated only with DMSO.
The results obtained by studying the possible neuroprotective effects of our molecules against the effects of H 2 O 2 in the cells are shown in graphic 2.
From the 3-benzamidocoumarins 1-9, the most promising results against the effects of H 2 O 2 (graphic 2) corresponded, in general, to the derivatives presenting an hydroxyl group at position 4 of the coumarin scaffold and a single substituent in para position of the benzamide at position 3 (compounds 3, 7 and 9). In the case of 3-heteroarylamidoand 3-cyclohexanecarboxamidocoumarins 10-17 it was shown that the derivatives having a nicotinamide group at position 3 of the coumarin scaffold (compounds 14 and 15) exerted a statistically significant neuroprotection, whereas when the pyridine ring was substituted for a cyclohexane, thiophene or furan group, the compounds proved to be inactive against H 2 O 2 . Under these conditions, rasagiline (5µM) did not display significant neuroprotection. In view of these results it is possible that other mechanisms beyond MAO inhibition may be involved in the neuroprotective activity of these derivatives. Neuroprotection exerted by these compounds is concentration dependent. Therefore a decrease in the neuroprotection is observed when cultured rat cortical neurons were exposed to H 2 O 2 but treated with compounds 1-17 at 10 µM concentration. No significant differences were found for neurons treated with any compounds and exposed to H 2 O 2 (Table 3) . 
DPPH scavenging
Under normal conditions, free radicals are rapidly neutralized in the mitochondria, but over the years, this neutralization is no longer effective and dysfunction and even cell death occurs. We studied the DPPH (1,1-diphenyl-2-picrylhydrazyl) radical scavenging activity of those compounds showing best neuroprotective effects, in cells treated with H 2 O 2 (compounds 3, 7, 9, 14 and 15). As it can be seen in graphic 3, most of the studied compounds exerted free radical scavenging, being compounds 3 and 7 (100 µM) the most active derivatives, which showed a scavenging activity slightly higher than 50%. These are also two of the best compounds of the series of 3-benzamidocoumarins as neuroprotective agents against H 2 O 2 . By contrast, for the series of 3-nicotinamidocoumarins, compounds 14 and 15, only when a hydroxyl group is present at position 4 (compound 15) a free radical scavenging activity by approximately 20% was observed. Therefore, the presence of a hydroxyl group, in this specific case at position 4, seems to be critical for neutralization of free radicals by these derivatives.
Graphic 3. DPPH scavenging activity of coumarin derivatives 3, 7, 9, 14, 15 and vitamin C (positive control).
In vitro blood-brain barrier permeation assay
A basic condition of any compound to act on neurodegenerative processes is to penetrate into the brain, that is, to be able of crossing the blood-brain barrier (BBB). To examine the capability of our compounds to pass this barrier, we select compounds 3, 12, 14 and 15, some of the most active derivatives as MAO inhibitors and/or neuroprotective agents, and used a parallel artificial membrane model (PAMPA). [46] This is a fairly easy and successful method to predict the passive central nervous system (CNS) permeation, which had been previously optimized in order to be applied to investigational compounds with limited aqueous solubility. [47] [48] [49] Experimental results are represented in table 4. ), which is generally used as a standard of high permeability. In the case of compound 15, the passage through the BBB is doubtful (Pe = 9.3·10 -6 cm s -1 ).
Theoretical evaluation of ADME-related physicochemical/structural parameters
In order to better understand the overall properties and the drug-like characteristics of compounds 1-17, the lipophilicity (expressed as the octanol/water partition coefficient and herein called logP), and the theoretical prediction of other ADME properties (molecular weight, TPSA, number of hydrogen donors and acceptors, and volume)
were carried out with Molinspiration calculation software and are presented in the supplementary data. [50, 51] From the data presented in the supplementary data, it is significant that all the described derivatives possess logP values compatible with those required to cross membranes. Although TPSA (described to be a predictive indicator of membrane penetration) of selegiline is too different of those found to the studied compounds, all values were found to be in the desirable range. In addition, it can be observed that no 
Conclusions
In this study, a general and efficient synthesis of a new series of 3-amidocoumarins was developed, using an amidation reaction as key step. Determination of hMAO isoform activity was carried out, and many of the compounds exhibited selectivity for 
N-(4-
Pharmacological assays
Determination of MAO isoforms enzymatic activity
The tested compounds were dissolved in DMSO (Sigma-Aldrich, Alcobendas, Madrid, Spain) to prepare 10 mM stock solutions, which were kept for storage at -20 o C.
Percentage of DMSO used in the experiments was never higher than 1%. Selegiline and rasagiline, used as reference inhibitors, have been acquired from Sigma-Aldrich increased linearly. [43] Control experiments were carried out simultaneously by replacing the test drugs (new compounds and reference inhibitors) with appropriate dilutions of the vehicles. In addition, the possible capacity of the above test drugs to modify the fluorescence generated in the reaction mixture due to non-enzymatic inhibition (e.g., for directly reacting with Amplex ® Red reagent) was determined by adding these drugs to solutions containing only the Amplex ® Red reagent in a sodium phosphate buffer. To determine the kinetic parameters of hMAO-A and hMAO-B (K m and V max ), the corresponding enzymatic activity of both isoforms was evaluated (under the experimental conditions described above) in the presence of a number (a wide range) of p-tyramine concentrations.
The specific fluorescence emission (used to obtain the final results) was calculated after subtraction of the background activity, which was determined from wells containing all components except the hMAO isoforms, which were replaced by a sodium phosphate buffer solution. In our experimental conditions, this background activity was practically negligible.
MAO activity of the test compounds and reference inhibitors is expressed as IC 50 , e.g.
the concentration of each drug required to produce a 50% decreased on control value activity isoforms MAO.
Determination of inhibition mode
To evaluate whether compounds 1, 12, 14 and 17 are reversible or irreversible hMAO-B inhibitors, a dilution method was used. [44] A 100x concentration of the enzyme used in 
Primary culture of neurons and glia
Pregnant rats (19-20 days) were killed by CO 2 inhalation and embryos were immediately extracted from the womb by caesarean section and their brains were carefully dissected out. Meninges were removed and a portion of motor cortex was isolated after the dissection of the brain. [26] Fragments obtained from several embryos were subjected to mechanic disintegration. Neurobasal medium supplemented with 2% to each well to a final concentration of 10%. [52] After incubating for two hours at 37 °C, the medium was removed and formazan crystals formed were suspended in 100 µL/well of DMSO. The production of formazan by viable cells was quantified at 37 o C in a reader absorbance (Fluo-star Optima, BMG LABTECH, Offenburg, Germany) by determining the absorbance (570 nm). [53, 54] In addition, the possible capacity of the above test drugs to modify the absorbance generated by reaction with MTT was determined by adding these drugs to solutions containing only MTT reagent in neurobasal medium.
Determination of the neutralization of free radicals
DMSO, DPPH, ascorbic acid and ethanol were acquired from Sigma-Aldrich Química S.A., Alcobendas, Spain.
DPPH radical scavenging activity of each compound was determined as previously described with minor modifications. The DPPH radical was dissolved in ethanol (100 µM) and 99 μL of the solutions were transferred to each well of a 96-well microplate. 1 μL of compounds 3, 7, 9, 14 and 15 (100 μM, final concentration) in ethanol was added to each well of a 96 well microplate and the mixtures were incubated at room temperature for 30 min. Vit. C (100 μM) was used as a positive control in the experiments. The absorbance at 540 nm was measured using a microplate reader. The scavenging activity of each compound was estimated by comparing the DPPH absorbance value in the antioxidant-radical reaction mixture after subtraction of the background activity. [55] [56] [57] In vitro blood-brain barrier permeation assay Hydrocortisone, desipramine, promazine, aldosterone, caffeine, ofloxacin, corticosterone, imipramine, testosterone, verapamil, piroxicam, lipid pig brain, phosphate buffered saline solution at pH 7.4 (PBS) and dodecane were purchased from Sigma-Aldrich Química S.A., Alcobendas, Spain and Acros, Madrid, Spain.
Prediction of the brain penetration was evaluated using a PAMPA-BBB assay, in a similar manner as previously described. [46] [47] [48] [49] Pipetting was performed with a semi- ).
Compounds were dissolved in PBS: ethanol (70:30) at 10 µg mL -1 , filtered through a Millex filter, and then added to the donor wells (200 µL). The donor filter plate was carefully put on the acceptor plate to form a sandwich, which was left undisturbed for 240 min at 25 o C. After incubation, the donor plate is carefully removed and the concentration of compounds in the acceptor wells was determined by UV-Vis spectroscopy. Every sample is analyzed at five wavelengths, in four wells and at least in three independent runs, and the results are given as the mean ± standard deviation.
In each experiment, 10 quality control standards of known BBB permeability were included to validate the analysis set.
Theoretical evaluation of absorption, distribution, metabolism and excretion properties
The absorption, distribution, metabolism and excretion (ADME) properties of the studied compounds were calculated using the Molinspiration property programme.
LogP was calculated using the methodology developed by Molinspiration as a sum of fragment-based contributions and correction factors. [50] TPSA was calculated based on the methodology published by Ertl et al. as a sum of fragment contributions. [58] Oxygenand nitrogen-centred polar fragments were considered. [50] PSA has been shown to be a very good descriptor characterizing drug absorption, including intestinal absorption, bioavailability, Caco-2 permeability and blood-brain barrier penetration.
The method for calculation of molecule volume developed at Molinspiration is based on group contributions. These have been obtained by fitting the sum of fragment contributions to 'real' three dimensional (3D) volume for a training set of about 12,000, mostly drug-like molecules. 3D molecular geometries for a training set were fully optimized by the semi-empirical AM1 method.
Statistics
Results are expressed as mean of at least 3 experiments ± SEM or ± SD for bloodbrain barrier permeation assay. Statistically significant differences between two measurements (P <0.05, P <0.01 or P <0.001) were determined by analysis of variance (ANOVA) followed by the multiple comparison Dunnett's test. The graphical representation, the statistical analysis and calculation of IC 50 values were performed using GraphPad Prism (V 4.03) software (San Diego, USA).
